Fundraising Fox
🦊/Companies
Sign in

Argá Medtech

2 known investors

Find your way into Argá Medtech

Argá Medtech is developing a non-thermal cardiac ablation system based on a proprietary Pulsed Field Ablation (PFA) technology using sine wave energy and a proprietary catheter to treat atrial fibrillation and other heart arrhythmias. The system targets electrophysiology and interventional cardiology, aiming to improve the safety, speed, and long-term outcomes of cardiac ablation.

HardwareHealthtechMedical Devices

Investors · 2

Advent Life SciencesLondon
Gilde HealthcarereportedUtrecht · $1.1M – $55M

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Argá Medtech Reports 94% Lesion Durability and Strong Safety Profile in First-in-Human BURST-AF Trial of Single-Catheter PFA Systemfinance.yahoo.com · Feb 2026Argá Medtech secures EUR 54M for its atrial fibrillation treatmentggba.swiss · Mar 2024Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech - Gilde Healthcaregildehealthcare.com · Feb 2024Argá Medtech SA closes oversubscribed Series B - BioAlpsbioalps.org · Feb 2024Argá Medtech closes oversubscribed Series B funding for pulsed field ablation tech - MassDevicemassdevice.com · Feb 2024Argá Medtech | Advent Life Sciencesadventls.com · Dec 2022

Frequently asked questions

What does Argá Medtech do?
Argá Medtech is developing a non-thermal cardiac ablation system based on a proprietary Pulsed Field Ablation (PFA) technology using sine wave energy and a proprietary catheter to treat atrial fibrillation and other heart arrhythmias. The system targets electrophysiology and interventional cardiology, aiming to improve the safety, speed, and long-term outcomes of cardiac ablation.
Who are Argá Medtech's investors?
Argá Medtech's investors include Advent Life Sciences, Gilde Healthcare.